Not so InSURMOUNTable: Tirzepatide to Treat Obesity
Not so InSURMOUNTable: Tirzepatide to Treat Obesity is organized by Connect Educate Impact (CEI).
Initial Release Date: February 8, 2023
Planned Expiration Date: February 8, 2026
Description:
42% of American adults are obese, which often leads to type 2 diabetes, hypertension, and dyslipidemia. This course explores tirzepatide’s place in therapy to address this national epidemic.
Upon successful completion of this application-based course, participants should be able to:
• Summarize current obesity management strategies and the American Association of Clinical Endocrinology’s clinical practice guidelines for obesity
• Explain the mechanism of action of tripeptide for weight loss
• Assess the results of the SURMOUNT-1 trial
• Discuss the role of tripeptide as a treatment for weight loss
• Apply clinical implications of the SURMOUNT-1 trial to an obese patient case
Additional details will be posted as soon as information is available.